fb-pixel Skip to main content

More Life Sciences Headlines


FDA advisers offer a vote of confidence for gene therapies

An advisory panel of the US Food and Drug Administration voted this month to recommend two gene therapies from Cambridge-based Bluebird Bio, giving optimism to other companies that are developing similar gene therapies.

Third Rock raises $1.1 billion for its largest fund yet

The Boston venture capital firm plans to use the money to launch more biotechs, despite the sector’s recent downturn.

FDA advisory committee unanimous in support of Bluebird Bio’s two gene therapies

It’s a much-needed win for the struggling Cambridge biotech but doesn’t guarantee approval.

Bluebird Bio nears moment of truth as FDA evaluates its gene therapies

The approval or rejection of Bluebird’s gene therapies will be a make-or-break moment for the struggling Cambridge biotech firm.

Omicron booster shots are taking longer than expected. Will the wait be worth it?

Pfizer once promised to make updated COVID shots in 100 days. More than 200 days will have elapsed by the time the FDA meets to discuss plans for those boosters in late June.

Upstream Bio raises $200 million to develop treatment for severe asthma

The Waltham startup acquired the experimental antibody therapy from Japanese drug maker Astellas.

GSK to buy Cambridge vaccine startup Affinivax for $2.1b, with more payments possible

The local biotech is developing a shot that protects against 24 types of pneumococcal bacteria.

Flagship’s latest startup launches with bold claim: the discovery of thousands of new human proteins

The venture capital giant has committed $75 million to Cambridge biotech ProFound Therapeutics.